{"nctId":"NCT04047472","briefTitle":"Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Chinese Patients With Neovascular Age-Related Macular Degeneration","startDateStruct":{"date":"2019-11-29","type":"ACTUAL"},"conditions":["Neovascular Age-Related Macular Degeneration"],"count":397,"armGroups":[{"label":"Brolucizumab 6 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Brolucizumab 6mg"]},{"label":"Aflibercept 2 mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Aflibercept 2 mg"]}],"interventions":[{"name":"Brolucizumab 6mg","otherNames":["Beovu"]},{"name":"Aflibercept 2 mg","otherNames":["Eylea"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Written informed consent must be obtained before any assessment was performed.\n* Male or female Chinese participants ≥ 50 years of age at the time of screening.\n* Active CNV lesions secondary to AMD that affect the central subfield (including retinal angiomatous proliferation lesions with a CNV component) in the study eye at screening and confirmed by the Central Reading Center (CRC).\n* Total area of CNV (including both classic and occult components) must comprise \\> 50% of the total lesion area in the study eye at screening and confirmed by the CRC.\n* Intra and/or subretinal fluid affecting the central subfield of the study eye at screening and confirmed by the CRC.\n* BCVA between 78 and 23 letters, inclusive, in the study eye at screening and baseline using ETDRS testing.\n\nExclusion Criteria:\n\n* Any active intraocular or periocular infection or active intraocular inflammation (e.g., infectious conjunctivitis, keratitis, scleritis, endophthalmitis, infectious blepharitis, uveitis) in study eye at baseline.\n* Central subfield of the study eye affected by fibrosis or geographic atrophy assessed by color fundus photography at screening and confirmed by the CRC.\n* Total area of fibrosis ≥ 50% of the total lesion in the study eye at screening and confirmed by the CRC.\n* Subretinal blood affecting the foveal center point and/or ≥ 50% of the lesion of the study eye at screening and confirmed by the CRC.\n* Previous treatment with any approved or investigational drugs for nAMD in the study eye (other than vitamin supplements).\n* Retinal pigment epithelium rip/tear in the study eye at screening.\n* Current vitreous hemorrhage or history of vitreous hemorrhage in the study eye within 4 weeks prior to baseline.","healthyVolunteers":false,"sex":"ALL","minimumAge":"50 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline at Week 48 in Best-Corrected Visual Acuity in Study Eye","description":"BCVA was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts.\n\nVisual function of the study eye was assessed using the ETDRS protocol. Participants with a BCVA ETDRS letter score between 78 and 23 ETDRS letters (inclusive) at Screening and Baseline in the study eye were included.\n\nMin and max possible scores are 0-100 respectively. A higher score represents better functioning.\n\nLast observation carried forward (LOCF) was used for the imputation of missing values.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.9","spread":"0.82"},{"groupId":"OG001","value":"10.9","spread":"0.82"}]}]}]},{"type":"SECONDARY","title":"Average Change From Baseline Over the Period of Week 36 to Week 48 in Best-Corrected Visual Acuity in Study Eye","description":"BCVA was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts.\n\nVisual function of the study eye was assessed using the ETDRS protocol. Participants with a BCVA ETDRS letter score between 78 and 23 ETDRS letters (inclusive) at Screening and Baseline in the study eye were included.\n\nMin and max possible scores are 0-100 respectively. A higher score represents better functioning.\n\nLast observation carried forward (LOCF) was used for the imputation of missing values.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.7","spread":"0.78"},{"groupId":"OG001","value":"11.0","spread":"0.79"}]}]}]},{"type":"SECONDARY","title":"q12w Treatment Status at Week 48 (for Subjects Randomized to Brolucizumab 6 mg Only) - Probability","description":"The estimate for the proportion of participants with a positive q12w treatment status was derived from Kaplan-Meier time-to-event analyses for the event \"first q8w-need\", applying a \"q8w-need\" allocation in case of missing or confounded data attributable to lack of efficacy and/or lack of safety for the purpose of analysis. The proportion of participants with a positive q12w treatment status was derived as follows according to the \"sufficient efficacy and safety\" approach: the q8w-need assessment was imputed as \"Yes\" at the disease activity assessment (DAA) visit following early treatment/study discontinuation due to lack of efficacy and /or lack of safety of the study treatment (applicable to both missing and non-missing DAAs).","paramType":"NUMBER","dispersionType":"90% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.595","spread":null}]}]}]},{"type":"SECONDARY","title":"q12w Treatment Status at Week 48 Within the Subjects With no q8w Need During the First q12w Cycle (Week 16 and Week 20) (for Subjects Randomized to Brolucizumab 6 mg Only) - Probability","description":"The estimate for the proportion of participants with a positive q12w treatment status was derived from Kaplan-Meier time-to-event analyses for the event \"first q8w-need\", applying a \"q8w-need\" allocation in case of missing or confounded data attributable to lack of efficacy and/or lack of safety for the purpose of analysis.\n\nThe analysis of \"q12w treatment status within the participants randomized to brolucizumab 6 mg and with no q8w need during the first q12w cycle\" was based on the subset of FAS participants randomized to brolucizumab 6 mg with no identified q8w-need at Week 16 and Week 20.","paramType":"NUMBER","dispersionType":"90% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.860","spread":null}]}]}]},{"type":"SECONDARY","title":"Number (%) of Participants With q8w Treatment Need as Assessed by the Investigator at First Disease Activity Assessment (DAA) Visit","description":"For both arms, the treatment was initiated with 3 monthly injections at Weeks 0, 4 and 8 (loading phase). Week 12 was scheduled as a \"no injection visit\" for both arms per protocol. Therefore, by Week 16, the planned treatment exposure was identical between the treatment arms, allowing a matched comparison of brolucizumab and aflibercept up to 8 weeks after loading.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"47","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline at Each Study Visit in Best-Corrected Visual Acuity in Study Eye","description":"BCVA was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts.\n\nVisual function of the study eye was assessed using the ETDRS protocol. Participants with a BCVA ETDRS letter score between 78 and 23 ETDRS letters (inclusive) at Screening and Baseline in the study eye were included.\n\nMin and max possible scores are 0-100 respectively. A higher score represents better functioning.\n\nLast observation carried forward (LOCF) was used for the imputation of missing values.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.9","spread":"0.58"},{"groupId":"OG001","value":"4.2","spread":"0.58"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.1","spread":"0.61"},{"groupId":"OG001","value":"6.5","spread":"0.61"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.4","spread":"0.69"},{"groupId":"OG001","value":"8.4","spread":"0.69"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.3","spread":"0.74"},{"groupId":"OG001","value":"9.4","spread":"0.74"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.2","spread":"0.78"},{"groupId":"OG001","value":"10.5","spread":"0.79"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.3","spread":"0.81"},{"groupId":"OG001","value":"10.0","spread":"0.81"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.1","spread":"0.77"},{"groupId":"OG001","value":"11.0","spread":"0.77"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.2","spread":"0.78"},{"groupId":"OG001","value":"10.7","spread":"0.78"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.1","spread":"0.79"},{"groupId":"OG001","value":"11.1","spread":"0.80"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.7","spread":"0.79"},{"groupId":"OG001","value":"10.9","spread":"0.79"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.0","spread":"0.80"},{"groupId":"OG001","value":"11.2","spread":"0.80"}]}]}]},{"type":"SECONDARY","title":"Average Change From Baseline in Best Corrected Visual Acuity (Letters Read) From Week 4 or Week 12 up to Week 48 for the Study Eye","description":"BCVA was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts.\n\nVisual function of the study eye was assessed using the ETDRS protocol. Participants with a BCVA ETDRS letter score between 78 and 23 ETDRS letters (inclusive) at Screening and Baseline in the study eye were included.\n\nMin and max possible scores are 0-100 respectively. A higher score represents better functioning.\n\nLast observation carried forward (LOCF) was used for the imputation of missing values.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.3","spread":"0.68"},{"groupId":"OG001","value":"9.6","spread":"0.68"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.9","spread":"0.73"},{"groupId":"OG001","value":"10.4","spread":"0.74"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Best-Corrected Visual Acuity of 73 Letters or More at Each Visit","description":"BCVA was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts.\n\nVisual function of the study eye was assessed using the ETDRS protocol. Participants with a BCVA ETDRS letter score between 78 and 23 ETDRS letters (inclusive) at Screening and Baseline in the study eye were included.\n\nMin and max possible scores are 0-100 respectively. A higher score represents better functioning.\n\nLast observation carried forward (LOCF) was used for the imputation of missing values.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"60","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59","spread":null},{"groupId":"OG001","value":"70","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69","spread":null},{"groupId":"OG001","value":"74","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68","spread":null},{"groupId":"OG001","value":"86","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68","spread":null},{"groupId":"OG001","value":"78","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73","spread":null},{"groupId":"OG001","value":"82","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73","spread":null},{"groupId":"OG001","value":"85","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71","spread":null},{"groupId":"OG001","value":"87","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73","spread":null},{"groupId":"OG001","value":"84","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78","spread":null},{"groupId":"OG001","value":"92","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72","spread":null},{"groupId":"OG001","value":"86","spread":null}]}]}]},{"type":"SECONDARY","title":"Gain in BCVA (Letters Read): Number (%) of Participants Who Gained ≥ 5, ≥ 10 and ≥ 15 Letters in Best-correct Visual Acuity From Baseline or Reached BCVA ≥ 84 Letters at Week 48 for the Study Eye","description":"BCVA was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts.\n\nVisual function of the study eye was assessed using the ETDRS protocol. Participants with a BCVA ETDRS letter score between 78 and 23 ETDRS letters (inclusive) at Screening and Baseline in the study eye were included.\n\nMin and max possible scores are 0-100 respectively. A higher score represents better functioning.\n\nLast observation carried forward (LOCF) was used for the imputation of missing values.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"139","spread":null},{"groupId":"OG001","value":"146","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"103","spread":null},{"groupId":"OG001","value":"104","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68","spread":null},{"groupId":"OG001","value":"73","spread":null}]}]}]},{"type":"SECONDARY","title":"Gain in BCVA (Letters Read): Number (%) of Participants Who Gained ≥ 5 Letters in Best-correct Visual Acuity From Baseline or Reached BCVA >=84 Letters at the Post-baseline Visit for the Study Eye","description":"BCVA was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts.\n\nVisual function of the study eye was assessed using the ETDRS protocol. Participants with a BCVA ETDRS letter score between 78 and 23 ETDRS letters (inclusive) at Screening and Baseline in the study eye were included.\n\nMin and max possible scores are 0-100 respectively. A higher score represents better functioning.\n\nLast observation carried forward (LOCF) was used for the imputation of missing values.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73","spread":null},{"groupId":"OG001","value":"94","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"102","spread":null},{"groupId":"OG001","value":"115","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"122","spread":null},{"groupId":"OG001","value":"139","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"134","spread":null},{"groupId":"OG001","value":"149","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"133","spread":null},{"groupId":"OG001","value":"147","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"129","spread":null},{"groupId":"OG001","value":"149","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"134","spread":null},{"groupId":"OG001","value":"147","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"131","spread":null},{"groupId":"OG001","value":"154","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"129","spread":null},{"groupId":"OG001","value":"151","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"134","spread":null},{"groupId":"OG001","value":"152","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"136","spread":null},{"groupId":"OG001","value":"151","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"139","spread":null},{"groupId":"OG001","value":"146","spread":null}]}]}]},{"type":"SECONDARY","title":"Gain in BCVA (Letters Read): Number (%) of Participants Who Gained ≥ 10 Letters in Best-correct Visual Acuity From Baseline or Reached BCVA >=84 Letters at the Post-baseline Visit for the Study Eye","description":"BCVA was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts.\n\nVisual function of the study eye was assessed using the ETDRS protocol. Participants with a BCVA ETDRS letter score between 78 and 23 ETDRS letters (inclusive) at Screening and Baseline in the study eye were included.\n\nMin and max possible scores are 0-100 respectively. A higher score represents better functioning.\n\nLast observation carried forward (LOCF) was used for the imputation of missing values.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57","spread":null},{"groupId":"OG001","value":"59","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79","spread":null},{"groupId":"OG001","value":"85","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88","spread":null},{"groupId":"OG001","value":"93","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86","spread":null},{"groupId":"OG001","value":"107","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90","spread":null},{"groupId":"OG001","value":"98","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91","spread":null},{"groupId":"OG001","value":"108","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95","spread":null},{"groupId":"OG001","value":"107","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94","spread":null},{"groupId":"OG001","value":"108","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"102","spread":null},{"groupId":"OG001","value":"98","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"101","spread":null},{"groupId":"OG001","value":"107","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"103","spread":null},{"groupId":"OG001","value":"104","spread":null}]}]}]},{"type":"SECONDARY","title":"Gain in BCVA (Letters Read): Number (%) of Participants Who Gained ≥ 15 Letters in Best-correct Visual Acuity From Baseline or Reached BCVA >=84 Letters at the Post-baseline Visit for the Study Eye","description":"BCVA was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts.\n\nVisual function of the study eye was assessed using the ETDRS protocol. Participants with a BCVA ETDRS letter score between 78 and 23 ETDRS letters (inclusive) at Screening and Baseline in the study eye were included.\n\nMin and max possible scores are 0-100 respectively. A higher score represents better functioning.\n\nLast observation carried forward (LOCF) was used for the imputation of missing values.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null},{"groupId":"OG001","value":"28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":null},{"groupId":"OG001","value":"48","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null},{"groupId":"OG001","value":"55","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57","spread":null},{"groupId":"OG001","value":"59","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57","spread":null},{"groupId":"OG001","value":"54","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61","spread":null},{"groupId":"OG001","value":"64","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62","spread":null},{"groupId":"OG001","value":"64","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64","spread":null},{"groupId":"OG001","value":"69","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"66","spread":null},{"groupId":"OG001","value":"68","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63","spread":null},{"groupId":"OG001","value":"69","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68","spread":null},{"groupId":"OG001","value":"73","spread":null}]}]}]},{"type":"SECONDARY","title":"Loss in BCVA (Letters Read): Number (%) of Participants Who Lost ≥ 5, ≥ 10 and ≥ 15 Letters in Best-correct Visual Acuity From Baseline at Week 48 for the Study Eye","description":"BCVA was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts.\n\nVisual function of the study eye was assessed using the ETDRS protocol. Participants with a BCVA ETDRS letter score between 78 and 23 ETDRS letters (inclusive) at Screening and Baseline in the study eye were included.\n\nMin and max possible scores are 0-100 respectively. A higher score represents better functioning.\n\nLast observation carried forward (LOCF) was used for the imputation of missing values.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Loss in BCVA (Letters Read): Number (%) of Participants Who Lost ≥ 5 Letters in Best-correct Visual Acuity From Baseline to Each Post-baseline Visit for the Study","description":"BCVA was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts.\n\nVisual function of the study eye was assessed using the ETDRS protocol. Participants with a BCVA ETDRS letter score between 78 and 23 ETDRS letters (inclusive) at Screening and Baseline in the study eye were included.\n\nMin and max possible scores are 0-100 respectively. A higher score represents better functioning.\n\nLast observation carried forward (LOCF) was used for the imputation of missing values.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]}]},{"type":"SECONDARY","title":"Loss in BCVA (Letters Read): Number (%) of Participants Who Lost ≥ 10 Letters in Best-correct Visual Acuity From Baseline to Each Post-baseline Visit for the Study","description":"BCVA was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts.\n\nVisual function of the study eye was assessed using the ETDRS protocol. Participants with a BCVA ETDRS letter score between 78 and 23 ETDRS letters (inclusive) at Screening and Baseline in the study eye were included.\n\nMin and max possible scores are 0-100 respectively. A higher score represents better functioning.\n\nLast observation carried forward (LOCF) was used for the imputation of missing values.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"Loss in BCVA (Letters Read): Number (%) of Participants Who Lost ≥ 15 Letters in Best-correct Visual Acuity From Baseline to Each Post-baseline Visit for the Study","description":"BCVA was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts.\n\nVisual function of the study eye was assessed using the ETDRS protocol. Participants with a BCVA ETDRS letter score between 78 and 23 ETDRS letters (inclusive) at Screening and Baseline in the study eye were included.\n\nMin and max possible scores are 0-100 respectively. A higher score represents better functioning.\n\nLast observation carried forward (LOCF) was used for the imputation of missing values.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Average Change From Baseline Over the Period Week 4 Through Week 48 in Central Subfield Thickness - Total in Study Eye","description":"Central Subfield Thickness Assessed by Spectral domain optical coherence tomography (SD-OCT) from the central reading center.\n\nCentral subfield thickness (CSFT) is a key anatomical parameter of central macula and is the average thickness in the center subfield as measured from the Internal Limiting Membrane (ILM) to the Bruch's Membrane (BM). The center subfield is the circular region centered on the anatomic fovea with the radius of 500 μm.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-181.2","spread":"7.46"},{"groupId":"OG001","value":"-161.9","spread":"7.48"}]}]}]},{"type":"SECONDARY","title":"Average Change From Baseline Over the Period Week 36 Through 48 in Central Subfield Thickness - Total in Study Eye","description":"Central Subfield Thickness Assessed by Spectral domain optical coherence tomography (SD-OCT) from the central reading center.\n\nCentral subfield thickness (CSFT) is a key anatomical parameter of central macula and is the average thickness in the center subfield as measured from the Internal Limiting Membrane (ILM) to the Bruch's Membrane (BM).\n\nThe center subfield is the circular region centered on the anatomic fovea with the radius of 500 μm.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-187.9","spread":"8.38"},{"groupId":"OG001","value":"-167.2","spread":"8.40"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline at Each Study Visit in Central Subfield Thickness - Total in Study Eye","description":"Central Subfield Thickness Assessed by Spectral domain optical coherence tomography (SD-OCT) from the central reading center.\n\nCentral subfield thickness (CSFT) is a key anatomical parameter of central macula and is the average thickness in the center subfield as measured from the Internal Limiting Membrane (ILM) to the Bruch's Membrane (BM).\n\nThe center subfield is the circular region centered on the anatomic fovea with the radius of 500 μm.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-148.5","spread":"6.50"},{"groupId":"OG001","value":"-132.5","spread":"6.51"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-183.3","spread":"6.95"},{"groupId":"OG001","value":"-161.8","spread":"6.97"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-193.2","spread":"7.22"},{"groupId":"OG001","value":"-169.9","spread":"7.24"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-179.5","spread":"7.99"},{"groupId":"OG001","value":"-152.6","spread":"8.01"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-172.2","spread":"7.91"},{"groupId":"OG001","value":"-175.6","spread":"7.93"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-185.2","spread":"8.33"},{"groupId":"OG001","value":"-152.0","spread":"8.35"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-186.8","spread":"8.06"},{"groupId":"OG001","value":"-172.0","spread":"8.08"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-174.0","spread":"8.37"},{"groupId":"OG001","value":"-157.2","spread":"8.39"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-191.2","spread":"8.29"},{"groupId":"OG001","value":"-171.3","spread":"8.31"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-184.6","spread":"8.57"},{"groupId":"OG001","value":"-159.0","spread":"8.59"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-184.7","spread":"8.64"},{"groupId":"OG001","value":"-175.3","spread":"8.66"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-191.1","spread":"8.71"},{"groupId":"OG001","value":"-163.2","spread":"8.73"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline at Each Study Visit in Central Subfield Thickness - Neurosensory Retina (μm) in Study Eye","description":"Central Subfield Thickness Assessed by Spectral domain optical coherence tomography (SD-OCT) from the central reading center.\n\nThe central subfield thickness-neurosensory retina (CSFTns) is the average thickness in the center subfield as measured from the Internal Limiting Membrane (ILM) to the outer segment tips.\n\nThe center subfield is the circular region centered on the anatomic fovea with the radius of 500μm.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-57.2","spread":"4.55"},{"groupId":"OG001","value":"-48.3","spread":"4.57"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-65.4","spread":"4.94"},{"groupId":"OG001","value":"-53.2","spread":"4.95"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-68.6","spread":"5.11"},{"groupId":"OG001","value":"-53.2","spread":"5.12"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-63.8","spread":"5.22"},{"groupId":"OG001","value":"-48.4","spread":"5.24"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-60.8","spread":"5.44"},{"groupId":"OG001","value":"-56.4","spread":"5.45"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-67.0","spread":"5.22"},{"groupId":"OG001","value":"-49.9","spread":"5.23"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-67.2","spread":"5.28"},{"groupId":"OG001","value":"-54.5","spread":"5.29"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-62.7","spread":"5.26"},{"groupId":"OG001","value":"-50.1","spread":"5.27"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-69.2","spread":"5.42"},{"groupId":"OG001","value":"-56.3","spread":"5.43"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-67.9","spread":"5.45"},{"groupId":"OG001","value":"-52.7","spread":"5.46"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-67.8","spread":"5.53"},{"groupId":"OG001","value":"-57.2","spread":"5.54"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-69.7","spread":"5.38"},{"groupId":"OG001","value":"-53.0","spread":"5.39"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Presence of Subretinal Field (SRF) and/or Intraretinal Fluid (Central Subfield) (IRF) in the Study Eye at Each Postbaseline Visit (and Specifically Week 16 and Week 48)","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78","spread":null},{"groupId":"OG001","value":"92","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"51","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null},{"groupId":"OG001","value":"44","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"63","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55","spread":null},{"groupId":"OG001","value":"37","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"63","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":null},{"groupId":"OG001","value":"40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55","spread":null},{"groupId":"OG001","value":"57","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null},{"groupId":"OG001","value":"40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null},{"groupId":"OG001","value":"56","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45","spread":null},{"groupId":"OG001","value":"37","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null},{"groupId":"OG001","value":"52","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Absence of Subretinal Field (SRF) and Intraretinal Fluid (Central Subfield) (IRF) in the Study Eye Between Week 36 and Week 48","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"137","spread":null},{"groupId":"OG001","value":"127","spread":null}]}]}]},{"type":"SECONDARY","title":"Subretinal Fluid (SRF) Status in the Central Subfield: Number of Subjects With Presence of SRF by Visit for the Study Eye","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"149","spread":null},{"groupId":"OG001","value":"156","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63","spread":null},{"groupId":"OG001","value":"83","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"42","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null},{"groupId":"OG001","value":"28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"49","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"46","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"49","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"43","spread":null}]}]}]},{"type":"SECONDARY","title":"Intraretinal Fluid (IRF) Status in the Central Subfield: Number of Subjects With Presence of IRF by Visit for the Study Eye","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83","spread":null},{"groupId":"OG001","value":"81","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]}]},{"type":"SECONDARY","title":"Subretinal Pigment Epithelium (Sub-RPE) Fluid Status in the Central Subfield: Number of Subjects With Presence of Sub-RPE by Visit for the Study Eye","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline at Weeks 12 and 48 in Choroidal Neovascularization (CNV) Lesion in Study Eye","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.395","spread":"0.1613"},{"groupId":"OG001","value":"-1.378","spread":"0.1617"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.034","spread":"0.2002"},{"groupId":"OG001","value":"-1.984","spread":"0.2007"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Presence of Fibrosis (Central Subfield) in the Study Eye by Visit","description":"As assessed by color fundus photography.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"24","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Subject Reported Outcomes (Visual Function Questionnaire-25) - Composite Score","description":"The VFQ-25 includes a series of 25 questions pertaining to vision or feelings about a vision condition. Answers are selected among a numbered list of possible responses, the values of which are ultimately recoded and converted to a 0 to 100 scale. Items within each subscale are averaged together to create 12 subscale scores. An overall composite score was calculated by averaging vision-targeted subscale scores, excluding the general health rating question. All items are scored so that a high score represents better visual functioning.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.0","spread":"13.03"},{"groupId":"OG001","value":"3.7","spread":"12.94"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":"14.00"},{"groupId":"OG001","value":"2.9","spread":"13.69"}]}]}]},{"type":"SECONDARY","title":"Change in Subject Reported Outcomes (Visual Function Questionnaire-25) - General Vision","description":"The VFQ-25 includes a series of 25 questions pertaining to vision or feelings about a vision condition. Answers are selected among a numbered list of possible responses, the values of which are ultimately recoded and converted to a 0 to 100 scale. Items within each subscale are averaged together to create 12 subscale scores. An overall composite score was calculated by averaging vision-targeted subscale scores, excluding the general health rating question. All items are scored so that a high score represents better visual functioning.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.7","spread":"17.88"},{"groupId":"OG001","value":"7.8","spread":"17.47"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.0","spread":"19.68"},{"groupId":"OG001","value":"6.4","spread":"16.89"}]}]}]},{"type":"SECONDARY","title":"Change in Subject Reported Outcomes (Visual Function Questionnaire-25) - Ocular Pain","description":"The VFQ-25 includes a series of 25 questions pertaining to vision or feelings about a vision condition. Answers are selected among a numbered list of possible responses, the values of which are ultimately recoded and converted to a 0 to 100 scale. Items within each subscale are averaged together to create 12 subscale scores. An overall composite score was calculated by averaging vision-targeted subscale scores, excluding the general health rating question. All items are scored so that a high score represents better visual functioning.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"17.68"},{"groupId":"OG001","value":"6.1","spread":"15.74"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":"19.37"},{"groupId":"OG001","value":"3.1","spread":"17.88"}]}]}]},{"type":"SECONDARY","title":"Change in Subject Reported Outcomes (Visual Function Questionnaire-25) - Near Activities","description":"The VFQ-25 includes a series of 25 questions pertaining to vision or feelings about a vision condition. Answers are selected among a numbered list of possible responses, the values of which are ultimately recoded and converted to a 0 to 100 scale. Items within each subscale are averaged together to create 12 subscale scores. An overall composite score was calculated by averaging vision-targeted subscale scores, excluding the general health rating question. All items are scored so that a high score represents better visual functioning.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.3","spread":"22.02"},{"groupId":"OG001","value":"5.8","spread":"21.03"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.1","spread":"23.28"},{"groupId":"OG001","value":"5.7","spread":"22.64"}]}]}]},{"type":"SECONDARY","title":"Change in Subject Reported Outcomes (Visual Function Questionnaire-25) - Distance Activities","description":"The VFQ-25 includes a series of 25 questions pertaining to vision or feelings about a vision condition. Answers are selected among a numbered list of possible responses, the values of which are ultimately recoded and converted to a 0 to 100 scale. Items within each subscale are averaged together to create 12 subscale scores. An overall composite score was calculated by averaging vision-targeted subscale scores, excluding the general health rating question. All items are scored so that a high score represents better visual functioning.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":"21.09"},{"groupId":"OG001","value":"4.2","spread":"20.07"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","spread":"20.62"},{"groupId":"OG001","value":"4.8","spread":"21.11"}]}]}]},{"type":"SECONDARY","title":"Change in Subject Reported Outcomes (Visual Function Questionnaire-25) - Social Functioning","description":"The VFQ-25 includes a series of 25 questions pertaining to vision or feelings about a vision condition. Answers are selected among a numbered list of possible responses, the values of which are ultimately recoded and converted to a 0 to 100 scale. Items within each subscale are averaged together to create 12 subscale scores. An overall composite score was calculated by averaging vision-targeted subscale scores, excluding the general health rating question. All items are scored so that a high score represents better visual functioning.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":"13.44"},{"groupId":"OG001","value":"2.4","spread":"14.50"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":"14.90"},{"groupId":"OG001","value":"0.8","spread":"15.83"}]}]}]},{"type":"SECONDARY","title":"Change in Subject Reported Outcomes (Visual Function Questionnaire-25) - Mental Health","description":"The VFQ-25 includes a series of 25 questions pertaining to vision or feelings about a vision condition. Answers are selected among a numbered list of possible responses, the values of which are ultimately recoded and converted to a 0 to 100 scale. Items within each subscale are averaged together to create 12 subscale scores. An overall composite score was calculated by averaging vision-targeted subscale scores, excluding the general health rating question. All items are scored so that a high score represents better visual functioning.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.6","spread":"25.61"},{"groupId":"OG001","value":"0.6","spread":"20.34"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.7","spread":"22.46"},{"groupId":"OG001","value":"1.0","spread":"21.55"}]}]}]},{"type":"SECONDARY","title":"Change in Subject Reported Outcomes (Visual Function Questionnaire-25) - Role Difficulties","description":"The VFQ-25 includes a series of 25 questions pertaining to vision or feelings about a vision condition. Answers are selected among a numbered list of possible responses, the values of which are ultimately recoded and converted to a 0 to 100 scale. Items within each subscale are averaged together to create 12 subscale scores. An overall composite score was calculated by averaging vision-targeted subscale scores, excluding the general health rating question. All items are scored so that a high score represents better visual functioning.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"27.25"},{"groupId":"OG001","value":"3.8","spread":"25.91"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.5","spread":"25.23"},{"groupId":"OG001","value":"2.7","spread":"25.68"}]}]}]},{"type":"SECONDARY","title":"Change in Subject Reported Outcomes (Visual Function Questionnaire-25) - Dependency","description":"The VFQ-25 includes a series of 25 questions pertaining to vision or feelings about a vision condition. Answers are selected among a numbered list of possible responses, the values of which are ultimately recoded and converted to a 0 to 100 scale. Items within each subscale are averaged together to create 12 subscale scores. An overall composite score was calculated by averaging vision-targeted subscale scores, excluding the general health rating question. All items are scored so that a high score represents better visual functioning.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.9","spread":"28.38"},{"groupId":"OG001","value":"2.1","spread":"24.29"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.6","spread":"27.85"},{"groupId":"OG001","value":"0.6","spread":"26.50"}]}]}]},{"type":"SECONDARY","title":"Change in Subject Reported Outcomes (Visual Function Questionnaire-25) - Driving","description":"The VFQ-25 includes a series of 25 questions pertaining to vision or feelings about a vision condition. Answers are selected among a numbered list of possible responses, the values of which are ultimately recoded and converted to a 0 to 100 scale. Items within each subscale are averaged together to create 12 subscale scores. An overall composite score was calculated by averaging vision-targeted subscale scores, excluding the general health rating question. All items are scored so that a high score represents better visual functioning.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":"15.50"},{"groupId":"OG001","value":"0.8","spread":"19.65"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.9","spread":"17.28"},{"groupId":"OG001","value":"4.6","spread":"15.80"}]}]}]},{"type":"SECONDARY","title":"Change in Subject Reported Outcomes (Visual Function Questionnaire-25) - Color Vision","description":"The VFQ-25 includes a series of 25 questions pertaining to vision or feelings about a vision condition. Answers are selected among a numbered list of possible responses, the values of which are ultimately recoded and converted to a 0 to 100 scale. Items within each subscale are averaged together to create 12 subscale scores. An overall composite score was calculated by averaging vision-targeted subscale scores, excluding the general health rating question. All items are scored so that a high score represents better visual functioning.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":"12.95"},{"groupId":"OG001","value":"2.2","spread":"18.36"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"15.55"},{"groupId":"OG001","value":"0.5","spread":"14.93"}]}]}]},{"type":"SECONDARY","title":"Change in Subject Reported Outcomes (Visual Function Questionnaire-25) - Peripheral Vision","description":"The VFQ-25 includes a series of 25 questions pertaining to vision or feelings about a vision condition. Answers are selected among a numbered list of possible responses, the values of which are ultimately recoded and converted to a 0 to 100 scale. Items within each subscale are averaged together to create 12 subscale scores. An overall composite score was calculated by averaging vision-targeted subscale scores, excluding the general health rating question. All items are scored so that a high score represents better visual functioning.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":"17.76"},{"groupId":"OG001","value":"2.4","spread":"16.92"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"18.67"},{"groupId":"OG001","value":"1.4","spread":"19.60"}]}]}]},{"type":"SECONDARY","title":"Change in Subject Reported Outcomes (Visual Function Questionnaire-25) - General Health Rating","description":"The VFQ-25 includes a series of 25 questions pertaining to vision or feelings about a vision condition. Answers are selected among a numbered list of possible responses, the values of which are ultimately recoded and converted to a 0 to 100 scale. Items within each subscale are averaged together to create 12 subscale scores. An overall composite score was calculated by averaging vision-targeted subscale scores, excluding the general health rating question. All items are scored so that a high score represents better visual functioning.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.6","spread":"24.13"},{"groupId":"OG001","value":"0.7","spread":"24.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.4","spread":"24.84"},{"groupId":"OG001","value":"-2.7","spread":"26.62"}]}]}]},{"type":"SECONDARY","title":"Anti-drug Antibody (ADA): Frequency Distribution of Pre-dose ADA Status in the Brolucizumab Arm","description":"To assess immunogenicity of brolucizumab 6 mg.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"116","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-drug Antibody (ADA): Frequency Distribution of Integrated ADA Status in the Brolucizumab Arm","description":"To assess immunogenicity of brolucizumab 6 mg.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"170","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null}]}]}]},{"type":"SECONDARY","title":"Pharmacokinetic Parameters: Cmax After First Brolucizumab 6 mg Dose in a Subset of Subjects","description":"The maximum (peak) observed serum drug concentration after single dose administration (mass x volume-1)","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39.7","spread":"121.0"}]}]}]},{"type":"SECONDARY","title":"Pharmacokinetic Parameters: Tmax After First Brolucizumab 6 mg Dose in a Subset of Subjects","description":"The time to reach maximum (peak) serum drug concentration after single dose administration (time).\n\nActual sampling times were taken into consideration for the pharmacokinetic (PK) analysis.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.25","spread":null}]}]}]},{"type":"SECONDARY","title":"Pharmacokinetic Parameters: AUClast After First Brolucizumab 6 mg Dose in a Subset of Subjects","description":"The AUC from time zero to the last measurable concentration sampling time (tlast) (mass x time x volume-1)","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2690","spread":"74.4"}]}]}]},{"type":"SECONDARY","title":"Pharmacokinetic Parameters: AUCinf After First Brolucizumab 6 mg Dose in a Subset of Subjects","description":"The AUC from time zero to infinity (mass x time x volume-1)","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3100","spread":"73.4"}]}]}]},{"type":"SECONDARY","title":"Pharmacokinetic Parameters: T1/2 After First Brolucizumab 6 mg Dose in a Subset of Subjects","description":"The elimination half-life associated with the terminal slope (lz) of a semi logarithmic concentration time curve (time).","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"110","spread":"37.9"}]}]}]},{"type":"SECONDARY","title":"Pharmacokinetic Parameters: CL/F After First Brolucizumab 6 mg Dose in a Subset of Subjects","description":"Apparent total body clearance of siremadlin from serum (CL/F)","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.93","spread":"73.4"}]}]}]},{"type":"SECONDARY","title":"Pharmacokinetic Parameters: Vz/F After First Brolucizumab 6 mg Dose in a Subset of Subjects","description":"Apparent volume of distribution during terminal elimination phase (Vz/F)","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"307","spread":"48.6"}]}]}]},{"type":"SECONDARY","title":"Most Common Ocular Adverse Events (Greater Than or Equal to 2% in Any Treatment Arm) by Preferred Term for the Study Eye","description":"An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and unintended sign \\[including abnormal laboratory findings\\], symptom or disease) in a subject or clinical investigation subject.\n\nTreatment-emergent AEs are presented, which are AEs that developed on or after first study treatment administration, or any event previously present that worsened following exposure to the study treatment.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58","spread":null},{"groupId":"OG001","value":"48","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Non-ocular Adverse Events (Greater Than or Equal to 2% in Any Treatment Arm)","description":"An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and unintended sign \\[including abnormal laboratory findings\\], symptom or disease) in a subject or clinical investigation subject.\n\nTreatment-emergent AEs are counted, which are AEs that developed on or after first study treatment administration, or any event previously present that worsened following exposure to the study treatment.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97","spread":null},{"groupId":"OG001","value":"113","spread":null}]}]}]},{"type":"POST_HOC","title":"All Collected Deaths","description":"On-treatment deaths are reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum timeframe of approximately 48 weeks.\n\nPost-treatment deaths are reported 30 days after last treatment to 72 days post treatment (Day 185).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":23,"n":199},"commonTop":["COVID-19","Upper respiratory tract infection","Intraocular pressure increased - Study eye","Pyrexia","Cataract - Study eye"]}}}